The Hyderabad-based pharmaceutical major said its consolidated revenue from operations for the second quarter of FY26 stood at Rs 2,715 crore, reflecting a 16% YoY rise compared to Rs 2,338 crore reported in the September 2024 quarter.
Divi’s Laboratories earned a consolidated total income of Rs 2,860 crore for the quarter ended September 2025, compared to Rs 2,444 crore in the same quarter last year. Profit before tax (PBT) for the quarter came in at Rs 912 crore, up from Rs 722 crore a year ago.
Forex gains for the quarter stood at Rs 63 crore, higher than Rs 29 crore in the year-ago period.Half-year performance
For the half year ended September 2025, Divi’s Laboratories posted a consolidated total income of Rs 5,389 crore, compared to Rs 4,640 crore in the corresponding period last year.
Profit before tax for the six-month period was Rs 1,645 crore, up from Rs 1,326 crore a year ago, while profit after tax rose to Rs 1,234 crore from Rs 940 crore in the same period of the previous year.
Forex gains for the half year stood at Rs 102 crore compared to Rs 28 crore in the year-ago period.
Standalone performance
On a standalone basis, the company reported total income of Rs 2,806 crore for the quarter ended September 2025, compared to Rs 2,407 crore in the same quarter last year. Profit before tax rose to Rs 920 crore from Rs 735 crore a year ago, while profit after tax increased to Rs 696 crore from Rs 518 crore.
For the half year ended September 2025, total income stood at Rs 5,282 crore compared to Rs 4,548 crore in the corresponding period last year. Profit before tax was Rs 1,667 crore, up from Rs 1,338 crore, while profit after tax came in at Rs 1,253 crore versus Rs 948 crore a year ago.
Forex gains for the quarter were Rs 64 crore against Rs 27 crore in the year-ago quarter, and Rs 103 crore for the half year compared to Rs 26 crore in the same period last year.